Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18821417 | 0.91 | PPARG (0.37) | CNR2FAAHPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL18972304 | 0.87 | SLC6A9 (0.43) | PPARG | |
| SCHEMBL18907696 | 0.87 | FAAH (0.38) | CNR2FAAHPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL18961618 | 0.84 | SMN1; SMN2 (0.34) | CNR2MGLLALDH1A1TDP1 | |
| SCHEMBL18907918 | 0.81 | PTGDR2 (0.34) | PPARGCYSLTR2CYSLTR1 | |
| SCHEMBL18908287 | 0.79 | SMN1; SMN2 (0.34) | FAAH | |
| SCHEMBL18821425 | 0.78 | SLC6A9 (0.42) | PPARGALDH1A1L3MBTL1 | |
| SCHEMBL18914272 | 0.76 | ALOX15 (0.36) | — | |
| SCHEMBL18883443 | 0.75 | SMN1; SMN2 (0.33) | ALDH1A1TDP1 | |
| SCHEMBL18894946 | 0.74 | KDM4E (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091617-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | CNR2 3672/4885FAAH 1025/4885PPARG 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.